Home » Stocks » CSBR

Champions Oncology, Inc. (CSBR)

Stock Price: $10.14 USD 0.11 (1.10%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 134.30M
Revenue (ttm) 39.22M
Net Income (ttm) -1.23M
Shares Out 13.37M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE 59.17
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $10.14
Previous Close $10.03
Change ($) 0.11
Change (%) 1.10%
Day's Open 10.02
Day's Range 10.00 - 10.21
Day's Volume 22,116
52-Week Range 7.05 - 14.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Champions Oncology, Inc. (CSBR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 weeks ago - Zacks Investment Research

The markets keep going up as new stimulus spending and the massive new infrastructure bill hit. These micro-cap stocks are bargains.

Other stocks mentioned: ACU, BRBS, CFBK, ESCA, MRBK, SNFCA
1 month ago - InvestorPlace

Champions Oncology, Inc. (CSBR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...

1 month ago - Zacks Investment Research

HACKENSACK, NJ / ACCESSWIRE / March 11, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development thro...

1 month ago - Accesswire

HACKENSACK, NJ / ACCESSWIRE / March 5, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative ph...

2 months ago - Accesswire

Champions Oncology, Inc. (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

HACKENSACK, NJ / ACCESSWIRE / January 19, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-dri...

3 months ago - Accesswire

HACKENSACK, NJ / ACCESSWIRE / January 5, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driv...

4 months ago - Accesswire

Champions Oncology (CSBR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q1 2021 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Shares of Champions Oncology (NASDAQ:CSBR) were unchanged in after-market trading after the company reported Q1 results.

7 months ago - Benzinga

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q4 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Shares of Champions Oncology (NASDAQ:CSBR) rose 1.08% in after-market trading after the company reported Q4 results.

9 months ago - Benzinga

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Fiscal Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

In the long-run, does consistent market timing really matter to be a successful investor?

Other stocks mentioned: BSTC, CMD, RDNT, TRXC
1 year ago - Zacks Investment Research

Champions Oncology Inc (NASDAQ:CSBR) files its latest 10-K with SEC for the fiscal year ended on April 30, 2019.

1 year ago - GuruFocus

Champions Oncology, Inc. (CSBR) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

2 years ago - Zacks Investment Research

Champions Oncology is a profitable, free cash flow positive contract research organization serving the immune-oncology and oncology market.

2 years ago - Seeking Alpha

While the company reported a small (and unexpected) net loss in Q3 FY2019, it was a result of a one-time operational issue related to managing aggressive growth.

2 years ago - Seeking Alpha

Champions Oncology, Inc (CSBR) CEO Ronnie Morris on Q3 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About CSBR

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panel... [Read more...]

Industry
Biotechnology
IPO Date
Mar 25, 1986
Stock Exchange
NASDAQ
Ticker Symbol
CSBR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CSBR stock is "Strong Buy." The 12-month stock price forecast is 15.00, which is an increase of 47.93% from the latest price.

Price Target
$15.00
(47.93% upside)
Analyst Consensus: Strong Buy